- Volume 16 Issue 14
DOI QR Code
Salivary Her2/neu Levels in Differentiation of Oral Premalignant Disorders and Oral Squamous Cell Carcinomas
- Varun, Chopra (Oral and Maxillofacial Pathology, Indian Ocean Dental School and Hospital) ;
- Dineshkumar, Thayalan (Oral and Maxillofacial Pathology, SRM Dental College) ;
- Jayant, VS (Oral and Maxillofacial Pathology, SRM Dental College) ;
- Rameshkumar, Annasamy (Oral and Maxillofacial Pathology, SRM Dental College) ;
- Rajkumar, Krishnan (Oral and Maxillofacial Pathology, SRM Dental College) ;
- Rajashree, Padmanaban (Research Faculty, SRM Dental College) ;
- Mathew, Jacob (Department of Oral and Maxillofacial Pathology, Vinayaka Mission's Sankarachariyar Dental College) ;
- Arunvignesh, Rajendran K (Oral and Maxillofacial Pathology, SRM Dental College)
- Published : 2015.09.02
Background: Oral squamous cell carcinoma (OSCC) is thought to develop from precancerous dysplastic lesions through multistep processes of carcinogenesis involving activation of oncogenes and loss of tumor suppressor genes. The human epidermal growth factor receptor 2 (Her-2/neu [erbB-2]), a cell membrane glycoprotein, is a growth factor receptor that has receptor tyrosine kinase activity. Her2/neu activation plays a central role in cell proliferation and survival. It has been shown that overexpression of Her2/neu increases the rate of cell division and growth, leading to precancerous changes. The aim of the present study was to compare the serum and salivary Her2/neu levels between cases with premalignant and malignant oral lesions. Materials and Methods: Fasting blood samples and unstimulated saliva by passive drooling were collected from three groups of healthy control (n=20), premalignant disorder (PMD) (n=20) and OSCC (n=25) subjects. The HER2 extracellular domain (HER2 ECD) levels were measured using ELISA. Results: The levels of serum Her2/neu showed no significant differences between any of the groups but on the other hand salivary Her2/neu levels were found to be significantly (p<0.05) higher when compared between control (median 68.7 pg/ml, range: 21.5 - 75.8) and OSCC (median 145.6 pg/ml, range: 45.1-191.1). A similar trend was observed when comparing between PMD (median 43.3, range: 22.1 -94.7) and OSCC with a statistical significance of p<0.05. Conclusions: Our study provided evidence of increased salivary Her2/neu in OSCC when compared to PMD and control which was not the case for serum levels. This suggests that probably Her2/neu is not highly amplified as in breast cancer so as to be reflected in serum. Since saliva is in local vicinity of the OSCC, even a mild increase might be mirrored. On the whole, this study proposes Her2/neu as marker for distinguishing premalignant and malignant conditions.
- Chen CH, Lin YS, Lin CC, et al (2004). Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients. J Oral Pathol Med, 33, 89-94.
- Chen CH, Tsai TL, Yang YS, Tsai CC (2007). Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma. J Oral Pathol Med, 36, 83-7. https://doi.org/10.1111/j.1600-0714.2007.00502.x
- Citri A, Yarden Y (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 7, 505-16.
- Cross M, Dexter TM (1991). Growth factors in development, transformation, and tumorigenesis. Cell, 64, 271-80. https://doi.org/10.1016/0092-8674(91)90638-F
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Fong Y, Chou SJ, Hung KF, Wu HT, Kao SY (2008). An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. J Chin Med Assoc, 71, 123-27. https://doi.org/10.1016/S1726-4901(08)70003-0
- Henning H, Robert G, Alexander G, et al (2014). Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas. J Oral Pathol Med, 43, 304-8. https://doi.org/10.1111/jop.12173
- Hou L, Shi D, Tu SM, et al (1992). Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett, 65, 215-20. https://doi.org/10.1016/0304-3835(92)90234-M
- Ibrahim SO, Lillehaug JR, Johannessen AC, et al (1999). Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. Oral Oncol, 35, 302-13. https://doi.org/10.1016/S1368-8375(98)00120-1
- Khan AJ, King BL, Smith BD, et al (2002). Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res, 8, 540-8.
- Li B, Wang M, Wen Y, Chen J (1992). Erb-B oncogene in human oral squamous cell carcinomas. Hua Xi Yi Ke Da Xue Xue Bao, 23, 284-87.
- Lutfiye D, Seyran Y, Canan S, et al (2014). Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype? Asian Pac J Cancer Prev, 15, 9739-45. https://doi.org/10.7314/APJCP.2014.15.22.9739
- Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA (2007). Molecular genetics of premalignant oral lesions. Oral Dis, 13, 126-33. https://doi.org/10.1111/j.1601-0825.2006.01349.x
- Pinto LS, de Aguiar FC Jr, Kowalski LP, Graner E, Lopes MA (2010). FAS and ErbB2 expression in early local recurrent oral cancer. J Oral Pathol Med, 39, 176-81. https://doi.org/10.1111/j.1600-0714.2009.00822.x
- Safoura S, Shahriar S, Kamran N, Behzad A (2009). Lack of Elevated HER2/neu Expression in Epithelial Dysplasia and Oral Squamous Cell Carcinoma in Iran. Asian Pacific J Cancer Prev, 10, 661-4.
- Schartinger VH, Kacani L, Andrle J, et al (2004). Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec, 66, 21-6. https://doi.org/10.1159/000077229
- Stoicanescu D, Andreescu N, Belengeanu A, Meszaros N, Cornianu M (2013). Assessment of p53 and HER-2/neu genes status and protein products in oral squamous cell carcinomas. Rom J Morphol Embryol, 54, 1107-13.
- Tadokoro K, Ueda M, Ohshima T, et al (1989). Activation of oncogenes in human oral cancer cells: a novel codon 13 mutation of c-H-ras-1 and concurrent amplifications of c-erbB-1 and c-myc. Oncogene, 4, 499-505.
- Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG (2007). Advances in the biology of oral cancer. Oral Oncol, 43, 523-34. https://doi.org/10.1016/j.oraloncology.2006.11.010
- Vanessa FB, Frederico O, Silvia FS, et al (2010). Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. J Exp Clin Cancer Res, 29, 40. https://doi.org/10.1186/1756-9966-29-40
- Werkmeister R, Brandt B, Joos U (1999). Aberrations of erbB-1 and erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity. Br J Oral Maxillofac Surg, 37, 477-80. https://doi.org/10.1054/bjom.1999.0185
- Xia W, Lau YK, Zhang HZ, et al (1997). Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res, 3, 3-9.